Currently, in the immunotherapy of cancer, the most common targets within negative immune checkpoints are PD-1 (programmed death 1), its ligand PD-L1 (programmed death ligand 1), and CTLA-4 (cytotoxic T lymphocyte antigen 4) molecule when combination therapy is considered [3]. The gene discussed is CTLA4; the disease is cancer.